Kiniksa Pharmaceuticals International, plc (KNSA) Free cash flow 2017–2025
Kiniksa Pharmaceuticals International, plc (KNSA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$136.4MFY2025 · since FY2017: -$50.3M → $136.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $136.4M | +436.8% |
| FY2024 | $25.4M | +92.9% |
| FY2023 | $13.2M | +131.0% |
| FY2022 | $5.7M | +104.5% |
| FY2021 | -$126.7M | +7.4% |
| FY2020 | -$136.8M | +15.3% |
| FY2019 | -$161.6M | -87.2% |
| FY2018 | -$86.3M | -71.6% |
| FY2017 | -$50.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More KNSA financial trends
KNSA RevenueKNSA Net incomeKNSA Net marginKNSA Gross profitKNSA Gross marginKNSA Operating incomeKNSA Operating marginKNSA Operating cash flowKNSA Capital expendituresKNSA Return on equityKNSA Stock buybacksKNSA Dividends paidKNSA Total assetsKNSA Total liabilitiesKNSA Shareholders’ equityKNSA overview →